Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by PTGER4 is a member of the G-protein coupled receptor family. Additionally we are shipping PTGER4 Proteins (8) and many more products for this protein.
Showing 10 out of 80 products:
Human Polyclonal PTGER4 Primary Antibody for WB - ABIN1881704
Bastien, Sawyer, Grygorczyk, Metters, Adam: Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. in The Journal of biological chemistry 1994
Show all 4 Pubmed References
Human Polyclonal PTGER4 Primary Antibody for ELISA, WB - ABIN251245
Parida, Parekh, Dey, Ghosh, Mandal: Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model. in Cancer biology & therapy 2015
Show all 3 Pubmed References
Human Polyclonal PTGER4 Primary Antibody for ICC, IF - ABIN4348399
Prijatelj, Celhar, Mlinaric-Rascan: Prostaglandin EP4 receptor enhances BCR-induced apoptosis of immature B cells. in Prostaglandins & other lipid mediators 2011
Show all 2 Pubmed References
Human Polyclonal PTGER4 Primary Antibody for IHC, IHC (p) - ABIN4348401
Oll, Baumann, Behbahani, von Ruecker, Müller, Ellinger: Identification of prostaglandin receptors in human ureters. in BMC urology 2013
Human Polyclonal PTGER4 Primary Antibody for WB - ABIN519449
Xiao, Li, Jones-Brando, Yolken: Abnormalities of neurotransmitter and neuropeptide systems in human neuroepithelioma cells infected by three Toxoplasma strains. in Journal of neural transmission (Vienna, Austria : 1996) 2013
Lkt/ABCC4 (show ABCC4 Antibodies)-mediated PGE2 signalling acts through a ciliary G-protein-coupled receptor (show GPBAR1 Antibodies), EP4, to upregulate cAMP synthesis and increase anterograde intraflagellar transport, thereby promoting ciliogenesis.
Ep4a, a PGE2 receptor isoform of EP4, is involved in lymphoid precursor development in zebrafish.
These results indicate that the blockage of PGE2-EP4 signaling prevents the bone destruction required for prostate cancer metastases, and that this is, in part due to the abrogation of bone cell responses. The study provides further evidence that an EP4 antagonist is a candidate for the treatment of prostate cancer in the blockade of bone metastasis.
The results show that stimulation with the selective EP4 agonist CAY10598 or PGE2 promotes invadopodia-mediated degradation of the ECM (show MMRN1 Antibodies), as well as the invasion of breast cancer cells in in vitro models.
EP4 expression can promote the development of resistance to aromatase (show CYP19A1 Antibodies) inhibitor therapy for breast cancer
Findings suggest SUMO-1 (show SUMO1 Antibodies) protein and PGE2 receptor subtype 4 (EP4) as two potential targets for new therapeutic or prevention strategies for endometrial cancers.
GW627368X therefore effectively inhibits cervical cancer survival, motility, proliferation and angiogenesis by blocking EP4/EGFR (show EGFR Antibodies) interactive signaling.
The cross-talk between SP1 (show PSG1 Antibodies) and p65 (show GORASP1 Antibodies), and the positive feedback regulatory loop of PI3-K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies) signaling by EP4 contribute to the overall responses of solamargine in this process
The PTGER4 gene is a candidate risk factor for radiological progression in rheumatoid arthritis
IP and EP4 receptors have a role in prostanoid regulation of angiogeneis
miRNA 526b is a COX-2 (show COX2 Antibodies) upregulated, oncogenic miRNA promoting stem-like cells, the expression of which follows EP4 receptor-mediated signaling.
Altered inhibitory function of the EP4R in eosinophils and monocytes from aspirin-intolerant patients
These results demonstrate a novel role for prostaglandin receptor EP4 in the mediation of barrier-enhancing and anti-inflammatory effects caused by oxidized phospholipids.
The deletion of EP4 increases mitochondrial biogenesis and oxidative capacity in WAT, and fat mass loss ensues in mice.
Myeloid cell Ptger4 modulates interleukin production but not atherogenesis in type I diabetic mice.
These data suggest that vascular EP4 receptors buffer the actions of AngII on renal hemodynamics and oxidative injury.
these studies have demonstrated an important but unexpected role for macrophage COX-2 (show COX2 Antibodies)/prostaglandin E2/PGE2 receptor subtype 4 signaling to lessen progression of diabetic kidney disease, unlike the pathogenic effects of increased COX-2 (show COX2 Antibodies) expression in intrinsic renal cells.
data demonstrate that endogenous PGE2, EP2 (show SPAG11A Antibodies) receptors, and EPAC (show RAPGEF3 Antibodies) are prerequisites for maximal LPS (show TLR4 Antibodies)-induced IL-33 (show IL33 Antibodies) expression and that exogenous PGE2 can amplify IL-33 (show IL33 Antibodies) production via EP2 (show SPAG11A Antibodies) and EP4 receptors.
The data presented highlight a key role for EP2 (show SPAG11A Antibodies) and EP4 receptors in microvascular leak induced by PGE2.
These results suggest that Il23a (show IL23A Antibodies) expression in DCs is synergistically triggered by the PG E2-EP4-cAMP-PKA pathway and canonical/non-canonical NF-kappaB (show NFKB1 Antibodies) pathways and CREB (show CREB1 Antibodies) activated by CD40 (show CD40 Antibodies) stimulation.
autocrine prostaglandin E2 signaling through EP receptors is essential for optimal CD4 (show CD4 Antibodies)(+) T-cell activation.
PGE2-mediated EP4 signaling in myeloid cells promotes tumorigenesis.
Data suggest that lysophosphatidic acid (LPA (show PLG Antibodies)) up-regulates expression of SLCO2A1 (show SLCO2A1 Antibodies) (prostaglandin [PG] transporter), PTGER2 (show PTGER2 Antibodies)/PTGER4 (PG receptors EP2 (show SPAG11A Antibodies)/EP4), and mPGES1 (show PTGES Antibodies)/cPGES (show PTGES3 Antibodies) (microsomal/cytosolic PG E synthases) in luteal cells.
Data suggest that estradiol up-regulates mRNA and protein expression of 3 prostanoid receptors in oviduct smooth muscle: EP2/PTGER2 (show PTGER2 Antibodies) (prostaglandin E receptor 2); EP4/PTGER4 (prostaglandin E receptor 4); and FP/PTGFR (prostaglandin F2alpha receptor (show PTGFR Antibodies)).
The PGE2-mediated down-regulation of CD25 (show IL2RA Antibodies) expression on T cells is mediated via the EP4 receptor, although selective activation of the EP2 receptor up-regulates the CD25 (show IL2RA Antibodies) expression on these cells.
EP4 is undetectable in endometrium and myometrium during the estrous cycle
Quantitative RT-PCR revealed significant higher expression of EP2 (show SPAG11A Antibodies) and EP4 in the pre-ovulatory phase compared with the luteal phase in the bovine oviduct
The protein encoded by this gene is a member of the G-protein coupled receptor family. This protein is one of four receptors identified for prostaglandin E2 (PGE2). This receptor can activate T-cell factor signaling. It has been shown to mediate PGE2 induced expression of early growth response 1 (EGR1), regulate the level and stability of cyclooxygenase-2 mRNA, and lead to the phosphorylation of glycogen synthase kinase-3. Knockout studies in mice suggest that this receptor may be involved in the neonatal adaptation of circulatory system, osteoporosis, as well as initiation of skin immune responses.
prostaglandin E receptor 4, subtype EP4
, prostaglandin E2 receptor EP4 subtype
, prostaglandin E2 receptor subtype 4
, prostaglandin E receptor 4 (subtype EP4)
, prostaglandin E receptor 4
, prostaglandin E receptor 4 subtype EP4
, PGE receptor EP4 subtype
, PGE receptor, EP4 subtype
, PGE2 receptor EP4 subtype
, prostanoid EP4 receptor
, prostaglandin E receptor 4 (EP4 subtype)
, prostaglandin E receptor EP4 subtype
, prostaglandin E2 receptor type 4
, PGE receptor, subtype EP4
, prostaglandin receptor EP4 subtype
, prostaglandin E2 subtype EP4 receptor